Navigation Links
CHEST 2011: Embargoed studies highlight new lung cancer and COPD research
Date:10/23/2011

Detroit Holds Record for Highest Lung Cancer Mortality Rates
(#1111771, Tuesday, October 25, 3:00 PM Eastern)

Compared with other cities, Detroit has one of the highest mortality rates in the United States for non-small cell lung cancer (NSCLC). Based on data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program, researchers from the McLaren Regional Medical Center in Flint, Michigan and the Mayo Clinic, in Minneapolis, Minnesota studied cancer-specific survival between Detroit and other city registries by ethnicity. They identified a total of 105,522 cases of small cell lung cancer and 3,094,764 cases of NSCLC. In all categories among ethnicities, Detroit showed lower survival rates than anywhere else in the United States. The differences in mortality existing between registries could reflect differences in health-care access and the stage of the tumor at the time discovered.

Conflicting Standards May Lead to Overdiagnosis or Underdiagnosis of COPD
(#1118428, Sunday, October 23, 4:45 PM Eastern)

Researchers from The Brooklyn Hospital Center in New York documented the diagnosis, stratification, and treatment discordance between the most widely accepted Global Initiative for Chronic Obstructive Lung Disease (GOLD) standards and the American Thoracic Society/European Respiratory Society (ATS/ERS) standards for COPD. After reviewing the pulmonary function reports of 217 patients with the clinical diagnosis of COPD, researchers found the rate of discordance was 11%, while four patients with a median age of 41 years met the ATS standards but not the GOLD standards. The conflicting diagnostic criteria, severity classification, and treatment recommendations create a dilemma in patient care, especially in patients with borderline diagnostic criteria and overlapping classifications of severity. Without this consensus, older patients may be overdiagnosed with COPD and younger patients underdiagnosed with COPD.

Canadian Patients With COPD Exacerbations More Likely to Delay Medical Attention
(#1104875, Tuesday, October 25, 3:00 PM Eastern)

COPD is identified as the leading cause of preventable hospitalizations in Canada. To understand how Canadian patients, physicians, and researchers perceive COPD compared with those in other nations, researchers from the Asthma and Airway Centre, University Health Network, and Family Physician Airways Group of Canada in Toronto surveyed 2,000 people from an international random sample of patients with COPD, primary care physicians, and respiratory specialists recruited from 14 nations. Of the Canadian patients (mean age, 62 years), 59% reported having at least one COPD exacerbation, while the overall percentage of patients reporting exacerbations was 69%. However, while 73% of international respondents would seek professional expertise during an exacerbation, only 55% of Canadians would do so. Although 28% of patients in other countries would seek professional help after 2 days, only 20% of Canadians sought assistance during that time. The 8% of patients typically taking no action was greater than the global average of 5%. Researchers concluded that a focus on self-management plans may reduce COPD exacerbation consequences in Canada.

Patients With COPD Can Be Diagnosed Via Presurgical Screening
(#1106050, Wednesday, October 26, 3:00 PM Eastern)

A recent study by Canadian researchers from Jewish General Hospital in Montreal, QC, Canada determined that, through a simple preoperative screening program, patients with previously undetected COPD may be diagnosed and appropriately managed. In a surgical preadmission clinic of a tertiary care university hospital in Montreal, current smokers and ex-smokers were questioned using the Canadian Health Lung Test to determine any respiratory symptoms. Between July 2010 and March 2011, 127 patients with a positive screening result were referred for spirometry, the standard diagnostic tool for COPD. Of the 43 patients with abnormal spirometry results, 22 patients (51%) represented newly found cases of COPD, 17 (40%) were known and confirmed cases, and 14 patients (82%) had at least moderate obstruction. Of the newly found cases of COPD, 14 patients (64%) had mild obstruction, which suggests that they were diagnosed at an earlier stage of the disease. Results suggest that preoperative screening may help identify patients with undiagnosed COPD, which may lead to earlier disease management and control of disease progression.

Proton Pump Inhibitors May Help Prevent Common Cold, COPD Exacerbations
(#1107813, Wednesday, October 26, 3:00 PM Eastern)

To determine whether proton pump inhibitors (PPIs) reduce the frequency of the common cold and resulting exacerbations among patients with COPD, Japanese researchers studied 100 former smokers with COPD, half who had received usual COPD therapies and PPIs and half who received only standard care. Both groups were observed for 12 months, and the frequency during which they caught colds was assessed. The number of acute exacerbations per person in that year within the PPI group was significantly lower than the control group that did not use PPIs; however, there was no significant difference between the numbers of common colds per person in 1 year in the PPI group and control group. This study demonstrated the beneficial effects of adding PPIs to the usual therapies for preventing COPD exacerbations.


'/>"/>

Contact: Sue Roberts
sroberts@chestnet.org
847-498-8334
American College of Chest Physicians
Source:Eurekalert

Related medicine news :

1. Rochester study: Age a big factor in prostate cancer deaths
2. Childrens Chest Pain Rarely Cause for Alarm: Study
3. How fair sanctions are orchestrated in the brain
4. Experts offer pointers for optimizing radiation dose in chest CT
5. Newsbriefs from the July issue of the journal Chest
6. Heart valve replacement without opening the chest gives new option for non-operable patients
7. Chest journal news briefs -- June 2011 issue
8. Chiropractic Spinal Manipulation Wont Cause Chest Injuries, Study Contends
9. Chiropractic manipulation results in little or no risk of chest injury
10. Breast Shield Better for Women Getting Chest CT Scan: Study
11. Low-dose chest CT effective in reducing radiation for evaluation of cardiothoracic surgery patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... ... A man who has struggled to quit smoking, a man who has struggled with hair ... solutions to his problems – and he did. Now Nabat, a serial entrepreneur featured as ... breakthrough inventions to the world and better people's lives. His own experience with nicotine addiction ...
(Date:2/8/2016)... ... 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the ... has teamed up with Citizens Opposed to Domestic Abuse in support of its efforts ... all those victimized by the fear of violence in their own homes, donations may ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest running and ... companies. Attendees also get to see the most incredible gardens and home improvement ... , at the Colorado Convention Center - 700 14th St. Denver CO, is an ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua ... on how healthcare companies can use newly released government data on populations and ... population and intervene and capture the value they create to succeed in new ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Company, Inc. (NYSE MKT: AXN) today announced that for the ... the Company achieved revenue of $8,195,839, a 27% improvement on ... 2015. --> --> The ... $2,068,635, or $.03 per share, up 265% from the net ... of fiscal year 2015. Gross margin for the three months ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
(Date:2/8/2016)... Calif. , Feb. 8, 2016  Sangamo ... in therapeutic genome editing, announced that the U.S. ... Company,s Investigational New Drug (IND) application for SB-318, ... life-long therapy for Mucopolysaccharidosis Type I (MPS I). ... enables Sangamo to initiate a Phase 1/2 clinical ...
Breaking Medicine Technology: